Showing 8471-8480 of 9370 results for "".
- Mount Sinai Wins $1.3M Grant to Expand Skin Biology Research Training Programhttps://practicaldermatology.com/news/mount-sinai-wins-13m-grant-to-expand-skin-biology-research-training-program/2461643/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arth
- New Way to Measure Skin Barrier Function Identifiedhttps://practicaldermatology.com/news/new-way-to-measure-skin-barrier-function-identified/2461628/Scientists in Japan have devised a new way to measure skin barrier function. Most methods indirectly calculate skin barrier function using a proxy measure called transepidermal water loss (TEWL), but the dependance on a heavily controlled environment is one of the primary limitations of this
- Takeda’s TYK2 Blocker Impresses in Phase 2b PsO Studyhttps://practicaldermatology.com/news/takedas-tyk2-blocker-impresses-in-phase-2b-pso-study/2461622/Takeda’s TYK2 inhibitor TAK-279 performed well in a Phase 2b study of patients with moderate-to-severe plaque psoriasis. TAK-279 was developed by Nimbus Therapeutics and owned by Takeda. The new findings were presented at the 2023 American Academy of Dermatology (AAD) An
- Molluscum Contagiosum Update: Two New Treatments Come Down the Pikehttps://practicaldermatology.com/news/molluscum-contagiosum-update-two-new-treatments-come-down-the-pike/2461621/Thanks to a busy pipeline, treating molluscum contagiosum may get easier. The U.S. Food and Drug Administration (FDA) accepted Novan’s New Drug Application (NDA) for Berdazimer Gel, 10.3% for the treatment of molluscum contagiosum with a Prescription Drug User Fee A
- Galderma's IL-31 Blocker Nemolizumab Wows in PNhttps://practicaldermatology.com/news/galdermas-il-31-blocker-nemolizumab-wows-in-pn/2461619/Galderma’s nemolizumab performed well in Prurigo Nodularis (PN). Nemolizumab is a first-in-class investigational monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31.Nemolizumab is an investigational drug and Galderma has not received
- Metal Implants May Cause Nickel Hypersensitivityhttps://practicaldermatology.com/news/metal-implants-may-cause-nickel-hypersensitivity/2461614/Dermatologists are seeing more patients concerned about a possible skin hypersensitivity to the nickel or other metals used in implanted medical devices. Millions of people in the U.S. report having a metal allergy, and current estimates state that 10 percent of Americans will receive a
- Cetaphil Celebrates Sensitive Skin with a Month of Skin Science Educationhttps://practicaldermatology.com/news/cetaphil-celebrates-sensitive-skin-with-a-month-of-skin-science-education/2461610/Cetaphil is ringing in the 2nd Annual Sensitive Skin Awareness initiative globally with a month of skin science education. Activating under the brand's campaign, "We Do Skin. You Do You," the global science effort will arm consumers with guidance on how to i
- National Society for Cutaneous Medicine Endorses Use of GEP Testing for Melanomahttps://practicaldermatology.com/news/national-society-for-cutaneous-medicine-endorses-use-of-gep-testing-for-melanoma/2461597/The National Society for Cutaneous Medicine now recommends use of gene expression profile (GEP) testing in the clinical assessment and management of cutaneous melanoma (CM). The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM
- International Women's Day: Botox Cosmetic, IFundWomen Partner for Grant Programhttps://practicaldermatology.com/news/international-womens-day-botox-cosmetic-ifundwomen-for-grant-program/2461596/In honor of International Women's Day, Allergan Aesthetics,’ an AbbVie company, is partnering with IFundWomen, the funding marketplace for women-owned businesses, on a grant program. Women entrepreneurs can apply for the opportunity to receive one of 20 grants worth
- Memantine May Improve Trichotillomania, Excoriation Disorderhttps://practicaldermatology.com/news/memantine-may-improve-trichotillomania-excoriation-disorder/2461594/The Alzheimer’s disease memantine effectively reduces symptoms of adults with trichotillomania and skin-picking disorder also known as excoriation disorder, new research shows. Researchers honed in on memantine based on earlier findings that revealed disorganized areas of white ma